Avaleht/Aktsiad/VERU

VERU

USD

Veru Inc. Common Stock

$0.653-0.007 (-1.061%)

Reaalajas hind

Healthcare

Biotehnoloogia

Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Turunäitajad

Avatud

$0.660

Kõrge

$0.685

Madal

$0.612

Maht

1.69M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

95.7M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

2.33M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $0.45Praegune $0.653Kõrge $1.42

Seotud uudised

28. mai 2025 · 10:30

GlobeNewswire

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and

Vaata rohkem

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

8. mai 2025 · 10:30

GlobeNewswire

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of

Vaata rohkem